Content |
NPO Petrovax Farm is one of the Russian companies developing and producing medicines and vaccines. The company was founded in 1996 by a team of Russian scientists with the aim of developing, producing and introducing original innovative medicines into healthcare practice. NPO Petrovax Farm has a research division and invests significant funds in its own developments, which allows us to bring to the market modern, popular, effective and safe drugs and vaccines, as well as quickly respond to changes in the field of medicine and the pharmaceutical industry.
2023: Production lines. Portfolio of manufactured medicines and vaccines
As of September 8, 2023, NPO Petrovax Farm launched four production lines for the production of drugs and vaccines in various forms: pre-filled syringes, ampoules, vials, tablets and suppositories. The maximum production capacity of the pharmaceutical complex is 160 million doses per year.
The portfolio of manufactured medicines and vaccines includes original drugs: Polyoxidonium and Longidase, influenza vaccines Grippol Plus, Grippol Quadrivalent, pneumococcal vaccine Prevenar 13, innovative thrombolytics Actilise and Metalise. Some of them are included in the List of vital and important drugs, supplied for the National Calendar of Preventive Vaccinations.
International projects on import substitution and localization of modern drugs have been implemented and are developing together with the world leaders of the pharmaceutical market: Abbott, Pfizer, Boehringer Ingelheim, ISU Abxis, Adimmune. The company's drugs are actively exported to the EAEU and EU markets.
The Petrovax production facility is licensed in accordance with the EAEU and EU GMP standards.
The production complex team is more than 400 employees, a quarter of whom are employed by the Department of Quality Control.
2022
Interros sold Petrovax Farm to top managers of the company and Ruben Vardanyan
On October 3, 2022, Interros announced the sale of 100% of Petrovax Farm to its top managers and investment company VB Partners Ruben Vardanyan and Mikhail Broitman. Its participants did not disclose the financial terms of the transaction.
Interros CEO Sergei Batekhin said the sale of assets was a logical step. According to him, over 8 years of cooperation, the company has fulfilled all its obligations, including the creation of a business development strategy and investments in the production of a wide range of new drugs.
Interos believes that participation in the transaction of the investment company VB Partners will contribute to the realization of the potential of Petrovax Farm. The company's strategy is aimed at creating and investing in sustainable businesses with an understandable business model and effective management - which fully reflects the vision of both the Petrovax team and the selling side.
The holding Vladimir Potanin recalled that Petrovax Farm produces a number of its own original drugs, localized drugs and vaccines, generics and biologically active additives. The company has its own research center and investment program for R&D management, it has patents in Russia and abroad for molecules and production technologies.
 | We are grateful to Interros for their expertise and contribution to the development of the company, which has undergone a significant transformation and managed to occupy new niches in the pharmaceutical markets not only in Russia, but also abroad. The buyback of the asset is the next logical step in development: the new shareholder structure will allow the company to continue to grow and provide comfort for all stakeholders, - said the president of Petrovaks Mikhail Tsyferov. |  |
By October 2022, Petrovax Farm supplies its products to 12 EAEU and EU countries.[1]
Production of drugs for the treatment of rare diseases is launched in Podolsk
In August 2022, NPO Petrovax Farm announced the construction of an enterprise in Podolsk for the production of drugs for the treatment of rare disabling orphan diseases.
We are talking about the second stage of the project. As part of the first stage, serial production of injectable drugs with a capacity of 50 million doses per year was launched. In the second phase, a four-story building with a total area of more than 3 thousand square meters will be erected.
Investments in the project will amount to 2 billion rubles. The new lines will carry out the synthesis of substances and the production of biotechnological drugs. The products will be sold in,,, and in Russia Armenia Belarus Kazakhstan Kyrgyzstan the countries of the Asia-Pacific region. 70 more specialized specialists will be offered jobs. Construction scheduled to be completed in the third quarter of 2023.
NPO Petrovax Farm will produce drugs and vaccines for the treatment of cancer, autoimmune, infectious and orphan diseases in the city district of Podolsk. For example, a drug for the therapy of Fabry disease. By August 2022, 100% of deliveries are carried out by a European company, if it leaves the Russian market, children may be left without the necessary treatment. The domestic manufacturer will replace the imported one, the company said.
| | Podolsk is also open to new enterprises and innovative projects. The municipality provides all the necessary support to entrepreneurs. 745 large companies have already made their choice in favor of Podolsk. In the first half of this year alone, investments in the budget amounted to more than 15 billion rubles, - commented on the project of NPO Petrovax Farm, the head of the Podolsk city district Dmitry Zharikov.[2] | |
Launch of the production of injectable drugs for 1.6 billion rubles
In July 2022, Petrovax Farm launched the production of injectable drugs, in which the Russian pharmaceutical company invested about 1.6 billion rubles.
According to the press service of Petrovax Farm, the 4th production line for the production of injectable forms has been launched in the Moscow Region, thanks to which the company will be able to increase the production of socially significant drugs and vaccines. The line is designed for more than 50 million doses per year. Thanks to the project, it was possible to additionally create 35 new jobs, it is planned to double their number - up to 70 people.
On the line launched in July 2022, the production of a vaccine for the prevention of influenza "Grippol® Plus," which the company supplies to the Russian and foreign markets, has begun. Petrovax is the leader in the export of influenza vaccines, so more than 8.6 million doses of the vaccine were delivered abroad last year. In 2022, the company plans to increase supply volumes by more than 10%.
According to the director of production "Petrovax" Sergei Kerentsev, despite serious sanctions challenges, the company continues to work steadily, implements all the planned projects, and also makes new long-term plans.
| | We erected the 4th line in our production in just a year - this is a record time for any enterprise. At the beginning of 2022, the company received a certificate of compliance of the production site with GMP requirements, EEU including a new line, - said Kerentsev. | |
In the next five years, Petrovax plans to implement projects to expand pharmaceutical production, including for the production of orphan, oncological and autoimmune drugs. In addition, in May 2022, Petrovax Farm President Mikhail Tsyferov announced the company's plans to localize Fabrazim biosimilar (agalsidase beta) from Sanofi in Russia for the therapy of Fabri disease in partnership with the South Korean company ISU Abxis. [3]
2016: Petrovax will be the second site in the world to produce thrombolytics "Beringer Ingelheim"
Beringer Ingelheim and NPO Petrovax Farm signed an agreement in early summer 2016 to localize the full production cycle of modern drugs for the treatment of cardiovascular diseases.
For Beringer Ingelheim, this is the first localization of this level: the company plans to complete the transfer of technologies, quality control methods by 2019 and establish a full cycle of production of innovative biotechnological thrombolytics at the NPO Petrovax Farm in the Moscow Region. The capacities of the production complex will be able to fully meet the needs of Russian patients in these drugs.
CVD is a systemic problem
Cardiovascular diseases (CVD), and primarily heart attacks and strokes, remain one of the main threats to the life and health of Russian citizens. Despite the fact that thanks to the modernization of the health care system, mortality in vascular pathology, according to the Ministry of Health of the Russian Federation, decreased by 12%, annually more than 30 thousand Russians need effective thrombolytic therapy.
According to the State Duma Committee on Health Protection, in Russia, mortality from major non-communicable diseases, including cardiovascular diseases, is 68.5% of the total mortality of the population. For example, in 2015, according to the National Register, 420 thousand Russians suffered an ischemic stroke, and effective thrombolytic therapy could not only save their lives, but also prevent the negative consequences of the disease.
In 2014, in the structure of total mortality, CVDs caused almost half of all deaths and about a third of all deaths of working age. According to experts, stroke in the structure of mortality is in second place, passing forward only myocardial infarction. However, now every year mortality is decreasing. Compared to five to seven years ago, when Russia ranked one of the first in Europe in terms of stroke mortality, we took a huge step forward.
More than 30 thousand people undergo treatment with BI thrombolytics every year - behind these figures are the lives of real people who got a chance to recover thanks to innovative drugs. Thrombolytic therapy allows halving the mortality rate of patients with acute myocardial infarction and significantly reducing the disability of patients who have had an ischemic stroke.
It is important to take into account the territorial specifics, which are fundamental for Russia. In Europe, there is a better chance of taking the patient to the hospital quickly and performing percutaneous coronary intervention. In Russia, where patients do not seek medical care right away, and where sometimes the ambulance route from the patient's house to the hospital is up to 60 km, prehospital (thrombolytic) therapy for myocardial infarction comes to the fore. BI thrombolytic with a single bolus administration allows you to immediately provide medical care to patients with acute myocardial infarction and has optimal properties for use by ambulance teams. The responsiveness of medical care is a determining factor in strokes as well. The biotechnological drug of Beringer Ingelzeim is the only thrombolytic indicated for the treatment of patients with ischemic stroke within 4.5 hours after the onset of symptoms.
By 2019, when the technology transfer process is fully completed, the partner companies have a lot of work to do. High-tech equipment will be installed and validated, production and quality control technologies will be transferred, and most importantly, Petrovax employees will be trained both in Russia and in. Within Germany the framework of the project, a team of Russian and German specialists will be formed, who will work in close cooperation. The most important stage will be the transfer of finished product quality control methods, and after reaching the planned capacity, Petrovax Farm will produce a sufficient number of drugs for at least 30 thousand patients per year with the possibility of increasing production in the future to meet the needs of all patients in. Russia
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |